



PRESS RELEASE

## **LAC Med Berhad Launches IPO Prospectus and eyes Main Market Debut**

- *Raising RM55.6 million to strengthen domestic presence, expands foothold in Indonesia*
- *Sets dividend policy to distribute at least 30% of annual audited net profit*
- *Applications for IPO open on 14 November, close on 25 November 2025*
- *To list on the Main Market of Bursa Malaysia on 10 December 2025*

Selangor, Malaysia, 14 November 2025 - LAC Med Berhad (LAC Med or the Group), a leading medical devices and integrated solutions provider, has launched its initial public offering (IPO) prospectus today in conjunction with its upcoming listing on the Main Market of Bursa Malaysia Securities Berhad on 10 December 2025.

The IPO exercise is expected to raise total proceeds of RM55.6 million, which will support the Group's plans to strengthen its domestic presence through new business segments, while expanding its regional footprint in Indonesia.

Of the total proceeds, RM8.0 million has been allocated to the launch of two new business segments, namely the Equipment-as-a-Service (EaaS) and the Medical Device Asset Management Services (MEAMS). Both initiatives are designed to enable healthcare providers to streamline operations, optimise asset utilisation, and strengthen LAC Med's recurring income base.

A further RM12.0 million will be used for setting up a new head office, which will feature an expanded storage facility and a dedicated showroom for product demonstrations. Meanwhile, RM8.0 million will be channelled towards the Group's regional expansion into Indonesia, where rising demand for healthcare infrastructure and medical devices presents strong growth opportunities. To capture this potential, LAC Med will progressively establish branch offices to extend the Group's reach and reinforce its commitment to delivering consistent service quality and technical support across the country.

The balance of the proceeds will be channelled for the repayment of borrowings, essential working capital, and defrayment of listing expenses.



“In 2025, LAC Med secured five new international brands to enhance our support for the healthcare sector, expanding our revenue streams with more diversified product offerings to fuel our growth. With a portfolio of 11 brands now, this reflects the confidence of our suppliers in the Group’s continued success.

As of now, we support Malaysia’s healthcare sector with an installed base of more than 2,500 units of medical equipment and over 300 active clients. This strong track record underscores our role as a trusted medical partner to both private and public healthcare service providers and the brand partners.

Through this IPO, we aim to strengthen our position in Malaysia by delivering medical devices and AI-powered integrated solutions that can enhance efficiency of healthcare service providers and improve patient care.

We also intend to extend our reach beyond Malaysia by expanding our presence in Indonesia in the coming years. Over the long term, we will leverage our track record and strong brand portfolio to replicate the success achieved at home and translate it into the Indonesian market.

We would like to express our sincere appreciation to our Principal Adviser, Sole Placement Agent, and Joint Underwriter, RHB Investment Bank, for their unwavering support throughout our IPO journey. We also extend our gratitude to Alliance Islamic Bank, our Joint Underwriter, for their valuable contribution and partnership.”

*Mr. Liew Yoon Poh (“刘任堡”)*

*Group Chief Executive Officer of LAC Med Berhad*

The IPO entails a total of 104.2 million ordinary shares in LAC Med priced at an initial price of RM0.75 per share, comprising 74.2 million new ordinary shares (Public Issue Shares) and up to 30.0 million existing ordinary shares (Offer for Sale Shares). The enlarged share capital upon the listing of LAC Med will comprise of 400.0 million shares and an enlarged indicative market capitalisation of RM300.0 million.

Of the Public Issue Shares, 50.0 million shares will be placed out to Bumiputera investors approved by the Ministry of Investment, Trade and Industry (MITI); 20.0 million shares will be made available for application by the Malaysian public through balloting, of which 50.0% will be set aside for Bumiputera investors; and the remaining 4.2 million shares will be made available for application by eligible directors, employees, and individuals who have contributed to the Group’s success (Eligible Persons).

Lastly, up to 30.0 million Offer for Sale Shares will be allocated to institutional and selected investors via private placement, which is expected to raise RM22.5 million for the Offerors of LAC Med Berhad.



“RHB Investment Bank is proud to support LAC Med Berhad in this significant milestone as they launch their IPO prospectus. Their comprehensive and integrated service offerings in healthcare solutions position them at the forefront of the evolving healthcare landscape with a clear vision to enhance patient care and operational efficiency for healthcare providers. This IPO presents an exciting opportunity for investors to participate in the growth of a home-grown company poised to deliver meaningful impact and long-term value across the healthcare and medical device sector.”

**Mr. Kevin Davies**

**Chief Executive Officer of RHB Investment Bank Berhad**

“Today marks an important milestone for LAC Med Berhad as it embarks on its listing journey. LAC Med’s strong fundamentals and focus on innovation in healthcare technology reflect its potential to deliver sustainable growth and long-term value for investors. Alliance Islamic Bank is proud to support this milestone as Joint Underwriter and to connect investors with promising home-grown companies that strengthen Malaysia’s healthcare ecosystem.”

**En. Rizal IL-Ehzan Bin Fadil Azim**

**Chief Executive Officer of Alliance Islamic Bank Berhad**

In addition to the growth proposition of LAC Med’s IPO, the Board has adopted a dividend policy to distribute at least 30.0% of annual audited net profit after tax to reward shareholders.

Applications for LAC Med’s IPO subscription will be made available starting today, 14 November 2025, and will close on 25 November 2025 at 5.00 pm.

RHB is the Principal Adviser, Joint Underwriter and Sole Placement Agent for the IPO, while Alliance is the Joint Underwriter.



- 1) Mr. Hong Chong Chet ("韩忠哲") - Deputy Chief Executive Officer of LAC Med Berhad
- 2) Mr. Goh Teck Hong ("吴德鸿") - Independent Non-Executive Director of LAC Med Berhad
- 3) Mr. Giam Teck Eng ("严德荣") - Substantial Shareholder of LAC Med Berhad
- 4) Mr. Tommy Har ("夏荣斌") - Executive Director, Co-Head, Corporate Finance of RHB Investment Bank Berhad
- 5) Mr. Liew Yoon Poh ("刘任堡") - Group Chief Executive Officer of LAC Med Berhad
- 6) Mr. Alex Liew Yoon Kit ("刘润杰") - Non-Independent Non-Executive Chairman of LAC Med Berhad
- 7) Ms. Teoh Chu Lin ("赵子霖") - Group Chief Corporate & Institutional Banking Officer of Alliance Bank Malaysia Berhad
- 8) Mr. Chan Yue Mun ("陈耀文") - Non-Independent Non-Executive Director of LAC Med Berhad
- 9) Dato' Ng Wan Peng ("黄婉冰") - Senior Independent Non-Executive Director of LAC Med Berhad
- 10) Ms. Lim Su May ("林素微") - Independent Non-Executive Director of LAC Med Berhad
- 11) Ms. Thean Yain Peng ("鄧燕萍") - Chief Financial Officer of LAC Med Berhad



**About LAC Med Berhad (LAC Med; the Group)**

Established in 2003, LAC Med is a leading medical devices and integrated solutions provider. Through its subsidiaries, LAC Med has established itself as a trusted partner to service providers in the healthcare sector. LAC Med has installed an extensive base of more than 2,500 units of medical equipment and supports over 300 active clients across Malaysia's healthcare sector, including private and public healthcare institutions, university hospitals, local health offices, medical device suppliers and concessionaire companies.

LAC Med's competencies extend from initial preliminary planning and facility design, custom interior fit-outs, equipment procurement and installation, system integration, testing and commissioning, to post-installation support services including training, technical support and maintenance services.

As an authorised distributor in Malaysia and Indonesia, LAC Med supplies and installs third-party brands of medical devices comprising medical equipment and associated products, which include medical consumables and provision of software and system integration.

LAC Med represents leading international medical brands including Samsung and Philips, with which it holds long-standing relationships since 2013 and 2017 respectively. Since 2023, the Group has also been appointed as an authorised distributor for Stryker, LG, Epson, SwiftMR, Abbott, annalise.ai, Alpinion, Baxter and Bayer, significantly strengthening its portfolio and its ability to deliver complete solutions for clients.

LAC Med remains committed to delivering innovative solutions that enhance healthcare efficiency and patient outcomes across Malaysia and the region.

**Issued for and on behalf of LAC MED BERHAD by Aquilas Advisory (Malaysia) Sdn Bhd.  
For media and investor relations enquiries, please contact:**

Mr. Terence Loo [terence@aquilas.com.my](mailto:terence@aquilas.com.my)

T:03-2711 1391/ M: 012-629 5618

Mr. Tee Wei Keat [weikeat@aquilas.com.my](mailto:weikeat@aquilas.com.my)

T:03-2711 1391/ M: 012-309 5448